A Phase I Clinical Trial to Evaluate:Part A. The Safety and Immunogenicity of Two Dose Levels of SF-2 gp120 (CHO) With or Without MTP-PE Adjuvant in the MF59 Emulsion Part B. The Safety and Immunogenicity of Five Monthly Doses of 50 mcg gp120 Protein in MF59 Emulsion (Without MTP-PE) Versus the Emulsion Control
Latest Information Update: 24 Mar 2014
At a glance
- Drugs HIV gp120 vaccine (Primary) ; MF 59; Mifamurtide
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 24 Mar 2014 New trial record